Market Overview

Endexx Sponsors 5th Annual Sophie's Day Golf Tournament benefiting the Leukemia and Lymphoma Society

Share:

CAVE CREEK, AZ, June 01, 2020 (GLOBE NEWSWIRE) --  via NEWMEDIAWIRE –Endexx Corporation, (OTC:EDXC) (the "Company" or a/k/a "CBD Unlimited"), a lifestyle company focused on the intersection of science, compliance, and formulation of innovative phytonutrient-based food and nutritional products, sponsors today's Annual golf tournament in honor of Sophie Lee with 100% of the proceeds benefiting the Leukemia & Lymphoma Society held at the Ancala Country Club in Scottsdale, AZ.

"Endexx is proud to sponsor the annual benefit sponsoring the Leukemia and Lymphoma Society and research into rare childhood cancer diseases. The Company is sponsoring the 10th hole and will be offering its topical CBD Unlimited products for use and sale. The products have proven to support golf patrons in their pursuit of a more comfortable golf experience including reduced fatigue and soreness.

"This is our fifth year of sponsorship and we have witnessed the community's effort to support families in their pursuit of advanced care for the patients with this devastating disease," commented Endexx and CBD Unlimited's Chief Executive Officer and Chairman, Todd Davis.

For donations and support please visit:

https://www.facebook.com/Sophiesdaygolf/?__tn__=K-R&eid=ARAk6iAAn2L542nMNlnWU1mkxYjHc6tolx19H_5UUnek-ZWeIjxVOuYYwskNggLcmQ0km6_Tp5t-vqtS&fref=mentions

About Endexx Corporation and CBD Unlimited

Endexx Corporation, through its operating division CBD Unlimited, develops and distributes all-natural CBD products derived from cannabis sativa plant (Hemp), containing less than 0.01% THC. Its products range from oils, capsules, topicals, and pet products, all with the shared purpose of therapeutic and pain relief for humans and pets. Phyto-Bites are CBD soft chews for animal use that are formulated to promote health and support the reduction of separation anxiety, pain, and inflammation. The science behind these products involves over half a decade of clinical research in the field and lab work in order to protect the accuracy in dosage and delivery of absorption per each serving.

In the interest of providing conformity with federal and state mandates, the company has incorporated the "Gorilla-Tek" platform into its business practices. The Gorilla-Tek platform is the first standardized hardware agnostic and software solution that tracks high-risk, high-shrink regulated, and restricted products maintained under federal/state/local compliance. The platform provides asset protection, inventory management, compliance, and an "end of sale" technology integration. Based on principles developed by the pharmacological industry, the integrated "Gorilla-Tek" platform is tremendously efficient as it provides up-to-the-minute accounting and product details. Gorilla-Tek increases productivity while reducing costs for retailers and costs in time for customers.

Safe Harbor Notice

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.

Contact:
For further investor and media information, please contact:
Endexx Corporation
Todd Davis, Chairman and CEO
endexx@endexx.com
480-595-6900

Primary Logo

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com